Abstract
Clusterin (CLU) is the third most important associated risk gene in cognitive disorders. Regarding the controversy about the association of CLU rs11136000 with mild cognitive impairment (MCI), the aim of this study was to investigate a putative association of CLU rs11136000 with MCI as well as the serum biological factors with a special attention to the age as a main dimension of a multifactorial elderly disease in an Iranian elderly cohort in which the mentioned association was not previously investigated. The study also checked the association between diabetes and MCI in this population. A population of 418 individuals containing 236 MCI and 192 control subjects was recruited from the Amirkola health and aging population cohort. Serum biological indexes were assessed by biochemical and enzyme-linked immunosorbent assay, and rs11136000 genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism. Bioinformatics analyses were used to identify the putative effect of rs11136000 on the secondary structure of RNA and chromatin location in different cell lines and tissues. Type 2 diabetes was present with a higher proportion in the MCI group in comparison with the control group (P = 0.041). The frequency of the C allele of CLU rs11136000 was significantly different between cases and controls and was associated with MCI risk (OR 1.79, P = 0.019). Under a dominant genetic model, the CC genotype showed a predisposing effect in individuals aged ≥ 75 years (OR 3.33, P = 0.0004). Interestingly, under an over-dominant model, the CT genotype had a protective effect in this population (OR 4.52, P = < 0.0001). We also found a significant association between the genotypes and high-density lipoprotein (HDL) levels in MCI patients (P = 0.0004). Bioinformatics analysis showed that rs11136000 is located in the transcribed region without any regulatory features such as being enhancer or insulator. Also, the T>C transition of CLU rs11136000 could not cause significant mRNA folding (P = 0.950). Contrary to other studies on Asian populations, this study demonstrated an association between rs11136000 and MCI in an elderly Iranian population. This study also suggests that an age-dependent approach to the previous studies may be performed in order to revise the previous belief in this geographical area. The rs11136000 genotypes in combination with HDL levels and knowledge about diabetes background may be used as a predictive medicine tool for cognitive disorders.
Similar content being viewed by others
References
Mariani E, Monastero R, Mecocci P (2007) Mild cognitive impairment: a systematic review. J Alzheimers Dis 12(1):23–35
Jaul E, Barron J (2017) Age-related diseases and clinical and public health implications for the 85 years old and over population. Front Public Health 5:335
Chentli F, Azzoug S, Mahgoun S (2015) Diabetes mellitus in elderly. Indian J Endocrinol Metab 19(6):744–752
Cukierman T, Gerstein H, Williamson J (2005) Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia 48(12):2460–2469
Cheng G et al (2012) Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J 42(5):484–491
de Silva HV et al (1990) Apolipoprotein J: structure and tissue distribution. Biochemistry 29(22):5380–5389
Thambisetty M et al (2012) Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 59(1):212–217
Thambisetty M et al (2013) Alzheimer risk variant CLU and brain function during aging. Biol Psychiatr 73(5):399–405
Thambisetty M et al (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatr 67(7):739–748
Park S, Mathis K, Lee I (2014) The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. Rev Endocr Metab Disord 15(1):45–53
Haase CL et al (2015) HDL cholesterol and risk of type 2 diabetes: a mendelian randomization study. Diabetes 64(9):3328–3333
Park S, Mathis KW, Lee IK (2014) The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. Rev Endocr Metab Disord 15(1):45–53
Bertram L, Tanzi RE (2009) Genome-wide association studies in Alzheimer’s disease. Human Mol Genet 18(R2):R137–R145
Carrasquillo MM et al (2010) Replication of CLU, CR1, and PICALM associations with Alzheimer disease. Arch Neurol 67(8):961–964
Corneveaux JJ et al (2010) Association of CR1, CLU and PICALM with Alzheimer’s disease in a cohort of clinically characterized and neuropathologically verified individuals. Human Mol Genet 19(16):3295–3301
Harold D et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41(10):1088–1093
Lancaster TM et al (2015) Alzheimer’s disease risk variant in CLU is associated with neural inefficiency in healthy individuals. Alzheimer’s Dement 11(10):1144–1152
Bertram L et al (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39(1):17
Gu H et al (2011) Association of clusterin gene polymorphisms with late-onset Alzheimer’s disease. Dementia Geriatr Cognit Disord 32(3):198–201
Han Z et al (2018) Analyzing 74,248 samples confirms the association between clu rs11136000 polymorphism and Alzheimer’s disease in caucasian but not Chinese population. Sci Rep 8(1):11062
Jen MY, Gossman WG (2018) Predictive medicine. StatPearls, Orlando
Hosseini SR et al (2014) Cohort profile: the Amirkola health and ageing project (AHAP). Int J Epidemiol 43(5):1393–1400
Ansari NN et al (2010) Validation of a mini-mental state examination (MMSE) for the Persian population: a pilot study. Appl Neuropsychol 17(3):190–195
Ernst J, Kellis M (2012) ChromHMM: automating chromatin-state discovery and characterization. Nat Methods 9(3):215–216
Gonzalez JR et al (2007) SNPassoc: an R package to perform whole genome association studies. Bioinformatics 23(5):644–645
Allen M et al (2012) Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology 79(3):221–228
Rizzuto D et al (2012) Dementia after age 75: survival in different severity stages and years of life lost. Curr Alzheimer Res 9(7):795–800
Grundman M et al (2004) Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 61(1):59–66
Daimon M et al (2011) Association of the clusterin gene polymorphisms with type 2 diabetes mellitus. Metabolism 60(6):815–822
Han BH et al (2001) Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. Nat Med 7(3):338–343
Leskov KS et al (2003) Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 278(13):11590–11600
Saedi E et al (2016) Diabetes mellitus and cognitive impairments. World J Diabetes 7(17):412–422
Kodl CT, Seaquist ER (2008) Cognitive dysfunction and diabetes mellitus. Endocr Rev 29(4):494–511
Munshi MN (2017) Cognitive dysfunction in older adults with diabetes: what a clinician needs to know. Diabetes Care 40(4):461–467
Abbatecola AM et al (2006) Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 67(2):235–240
Bertram L, Tanzi RE (2009) Genome-wide association studies in Alzheimer’s disease. Hum Mol Genet 18(R2):R137–R145
Cai R et al (2016) Plasma clusterin and the CLU gene rs11136000 variant are associated with mild cognitive impairment in type 2 diabetic patients. Front Aging Neurosci 8:179
Tan L et al (2016) Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts. Sci Rep 6:26027
Morgantini C et al (2011) Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes 60(10):2617–2623
Gordon SM et al (2011) High density lipoprotein: it’s not just about lipid transport anymore. Trends Endocrinol Metab 22(1):9–15
Drew BG et al (2009) High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119(15):2103–2111
Brunham LR et al (2007) Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 13(3):340–347
Han R et al (2007) Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 50(9):1960–1968
Rojano E et al (2018) Regulatory variants: from detection to predicting impact. Brief Bioinform. https://doi.org/10.1093/bib/bby039
Acknowledgements
The authors would like to acknowledge all participants of this study. The present study was supported by a Grant No. 9339436 of Babol University of Medical Sciences, Babol, Iran.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Aghajanpour-Mir, M., Amjadi-Moheb, F., Dadkhah, T. et al. Informative combination of CLU rs11136000, serum HDL levels, diabetes, and age as a new piece of puzzle-picture of predictive medicine for cognitive disorders. Mol Biol Rep 46, 1033–1041 (2019). https://doi.org/10.1007/s11033-018-4561-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-018-4561-5